What kind of uptake can Gilead expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) injection ...

Yetzugo is a long-acting HIV-1 capsid inhibitor that reduces the risk of sexually acquired HIV in adults and adolescents.

Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

He affirmed that the new drug "could take the epidemic to the history books," according to Mother Jones.Yeztugo, based on the ...

June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections.

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

FDA approves Yeztugo HIV prevention injection showing 96% efficacy in clinical trials, but $14,000 cost creates significant ...

Yeztugo showed promising results in clinical trials. One study involving women in Africa reported 100% efficacy, with zero ...